BSX – Market expectations are for Uniform ROA expansion, and management is confident about organic sales growth, operating margin, and China

December 7, 2021

Boston Scientific (BSX) currently trades near corporate and historical averages relative to Uniform earnings, with a 21.5x Uniform P/E (Fwd. V/E’).

At these levels, markets are pricing in expectations for Uniform ROA to recover to 25%, accompanied by 5% Uniform asset growth.

Meanwhile, analysts expect Uniform ROA to improve to 29% in 2022, accompanied by 6% Uniform asset growth.

If sustained going forward, these levels would imply a stock price closer to $45, representing approximately 17% equity upside for the firm.

Moreover, the firm’s most recent earnings call suggests management is confident about organic sales growth, operating margin, and China.

You don’t have access to the Valens Research Premium Application.

To get access to our best content including the highly regarded Conviction Long List and Market Phase Cycle macro newsletter, please contact our Client Relations Team at 630-841-0683 or email

Please fill out the fields below so that our client relations team can contact you

Or contact our Client Relationship Team at 630-841-0683